Drug Profile
Research programme: transmembrane protein modulators - AbCellera/Pfizer
Alternative Names: Function-modulating monoclonal antibodies - AbCellera/Pfizer; Monoclonal antibody (mAb) therapeutics - AbCellera/PfizerLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Abcellera
- Developer Abcellera; Pfizer
- Class Monoclonal antibodies
- Mechanism of Action Membrane protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified